Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
原文出处：CNBC （本文由聚合程序自动采集，版权归原作者所有）
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
原文出处：CNBC （本文由聚合程序自动采集，版权归原作者所有）